IL27 and neoplasm: Indeed, we recently reported (Zhu et al., 2018) that systemic delivery of IL-27 using rAAV could inhibit tumor growth and significantly enhance cancer immunotherapy in a variety of mouse tumor models without causing significant toxicity.